Early Tx doesn't reduce risk for congenital toxoplasmosis

Article

Even though some European countries have been screening prenatally for congenital toxoplasmosis for about 30 years, authors of a systematic review of cohort studies on the subject say it is unclear whether early treatment significantly reduces risk for the infection in newborns.

Even though some European countries have been screening prenatally for congenital toxoplasmosis for about 30 years, authors of a systematic review of cohort studies on the subject say it is unclear whether early treatment significantly reduces risk for the infection in newborns.

Researchers included 26 studies in the meta-analysis. They calculated an adjusted odds ratio (OR 0.48; P=0.05) for mother-to-child transmission when treatment was started prenatally within 3 weeks of seroconversion versus when treatment was started after 8 or more weeks. And prenatal treatment did not significantly reduce the risk of clinical manifestations in infected live-born infants (adjusted OR for treated vs. untreated 1.11).

The researchers also found that increasing gestational age at seroconversion was associated with increased risk of mother-to-child transmission (OR 1.15) and decreased risk of intracranial lesions (0.91), but not with eye lesions (0.97).

Related Videos
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Deciding the best treatment for uterine fibroids | Image Credit: jeffersonhealth.org.
Clinical pearls of pediatric dermatology | Image Credit: profiles.ucsf.edu
Approaching inflammatory vulvovaginal diseases | Image Credit: profiles.ucsf.edu.
Related Content
© 2024 MJH Life Sciences

All rights reserved.